北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis
作者: Wang, Y.; Liu, D-H; Xu, L-P; Liu, K-Y; Chen, H.; Zhang, X-H; Chen, Y-H; Han, W.; Wang, F-R; Wang, J-Z; Yan, C-H; Huang, X-J
关键词: donor lymphocyte infusion ; relapse ; HLA-mismatched
刊名: BONE MARROW TRANSPLANTATION
发表日期: 2012-08-01
DOI: 10.1038/bmt.2011.213
卷: 47, 期:8, 页:1099-1104
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]: BONE-MARROW-TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; ACUTE MYELOID-LEUKEMIA ; COLONY-STIMULATING FACTOR ; ACUTE GVHD ; BLOOD ; FEASIBILITY ; PROPHYLAXIS ; THERAPY ; GRAFTS
英文摘要:

The role of donor lymphocyte infusion (DLI) in the prophylaxis of relapse has not been defined. We retrospectively analyzed the data from 88 patients with advanced-stage acute leukemia after HLA-mismatched/haploidentical hematopoietic SCT (HSCT) whose treatment did (n=61) or did not (n=27) include granulocyte CSF (GCSF)-primed PBPCs infusion (GPBPCI). The two groups were compared with respect to relapse and OS. Further, a detailed analysis of risk factors was performed. The 2-year cumulative incidence of relapse in patients receiving prophylactic GPBPCI and not receiving prophylactic GPBPCI were 36% and 55% (P=0.017), respectively. Estimated survival at 3 years was 31% for patients receiving prophylactic GPBPCI and 11% for patients not receiving prophylactic GPBPCI (P=0.001). The three-year probability of leukemia-free survival was also higher in patients who received prophylactic GPBPCI (22%) compared with patients who did not (11%) (P=0.003). Multivariate analysis for relapse showed that use of prophylactic GPBPCI after transplantation was an independent prognostic factor (P=0.025). Higher OS was associated with use of prophylactic GPBPCI (P=0.002), AML (P=0.027) and female sex (P=0.023). Our results suggest that use of prophylactic GPBPCI may increase survival of patients with advanced-stage acute leukemia who receive HLA-mismatched/haploidentical HSCT.

语种: 英语
所属项目编号: 30971292 ; 2008zx09312-026
项目资助者: National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China (863 Program) ; Ministry of Health of China ; National Scientific Major Program-major new drug formulation ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation
WOS记录号: WOS:000307648300013
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52355
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China

Recommended Citation:
Wang, Y.,Liu, D-H,Xu, L-P,et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis[J]. BONE MARROW TRANSPLANTATION,2012,47(8):1099-1104.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Y.]'s Articles
[Liu, D-H]'s Articles
[Xu, L-P]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Y.]‘s Articles
[Liu, D-H]‘s Articles
[Xu, L-P]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace